FLGT250117C12500
- 7.95
- 0.000.00%
Fulgent Genetics Newsroom
Fulgent Genetics Is Maintained at Neutral by Piper Sandler
Fulgent Genetics Analyst Ratings
Piper Sandler Maintains Fulgent Genetics(FLGT.US) With Hold Rating, Cuts Target Price to $22
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fulgent Genetics (FLGT), Cigna (CI) and PROCEPT BioRobotics (PRCT)
Fulgent Genetics Analyst Ratings
Piper Sandler Sticks to Its Hold Rating for Fulgent Genetics (FLGT)
UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating
UBS Initiates Coverage On Fulgent Genetics With Neutral Rating, Announces Price Target of $35
Fulgent Genetics Analyst Ratings
Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $28
Fulgent Genetics Analyst Ratings
Piper Sandler Sticks to Their Hold Rating for Fulgent Genetics (FLGT)
Credit Suisse Lowers Fulgent Genetics' Price Target to $45 From $50 After Mixed Q4 Results, Keeps Outperform Rating
Credit Suisse Maintains Outperform on Fulgent Genetics, Lowers Price Target to $45
Fulgent Genetics (FLGT) Gets a Buy From Raymond James
Fulgent Genetics Analyst Ratings
Piper Sandler Downgrades Fulgent Genetics to Neutral, Lowers Price Target to $40
Fulgent Genetics Analyst Ratings
Raymond James Initiates Coverage On Fulgent Genetics With Outperform Rating, Announces Price Target of $45
Credit Suisse Adjusts Fulgent Genetics' Price Target to $50 From $65, Keeps Outperform Rating